Perspectives on Updated McDonald Criteria to Transform MS Diagnosis: Wallace Brownlee, MBChB, PhD, FRACP
The consultant neurologist at Queen's Square MS Center in London gave his clinical viewpoint on the newest revision of the McDonald criteria for diagnosing patients with multiple sclerosis. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
“I view this as a significant shift in how we diagnose MS, primarily because we no longer require a clinical syndrome, such as a relapse or progression. So, we’ll be diagnosing MS in patients with atypical symptoms or even no symptoms.”
The 2017 McDonald criteria initially created separate diagnostic standards for relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), based on historical precedents rather than biological differences. Despite this, a recent study presented at the
The study also highlighted the feasibility of including the optic nerve as a fifth area of involvement and incorporating multiple spinal cord lesions into the dissemination in space criteria for PPMS. Overall, these findings suggested that future updates to the McDonald criteria could benefit from adopting a unified approach for diagnosing MS, aligning more closely with biological evidence while simplifying the diagnostic process in clinical practice.1
Brownlee, a consultant neurologist at Queen's Square MS Center in London, United Kingdom, had an interview with NeurologyLive® during the Congress to discuss how the newly updated criteria presented at the meeting will impact the clinical approach to diagnosing MS in patients with atypical or absent symptoms. He also talked about the implications of using unified diagnostic criteria for both relapsing-remitting and primary progressive MS. Moreover, Brownlee spoke about how global healthcare systems can ensure equitable access to MS diagnosis given the updated criteria and resource disparities.
REFERENCES
1. Brownlee W, Vidal-Jordana A, Shatila M, et al. Towards a unified set of diagnostic criteria for multiple sclerosis. Presented at ECTRIMS Congress; September 18-20, 2024; Copenhagen, Denmark. Scientific Session 1: New diagnostic criteria. Abstract 1463.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025